Back to search
FDAFDA · Food and drugs·Recall number D-1001-2019

Docetaxel Injection USP, 80 mg/4 mL, (20 mg/mL), One-Vial Formulation, Rx only, Mfd By: Dr. Reddy's Laboratories Limited, Visakhapatnam - 530 046, Andhra Pradesh, INDIA, NDC 43598-259-40.

Published March 20, 2019 · Recall initiated: March 6, 2019

Summary

FDA records drug Class II recall D-1001-2019, published March 20, 2019 and initiated March 6, 2019. Recalling firm: Dr. Reddy's Laboratories, Inc.; Status: Terminated; Reported quantity: 5,755 vials; Lot: Lot#: H7081, Exp 07/2019. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Defective Container: complaint for seal and cap vial issues that could lead to a lack of sterility assurance.

What to do

Voluntary: Firm initiated · Letter

Get an email if DOCETAXEL has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DOCETAXEL
Manufacturer
Dr. Reddy's Laboratories, Inc.
Distributor
Nationwide in the USA
Lot
Lot#: H7081, Exp 07/2019
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Docetaxel Injection USP, 80 mg/4 mL, (20 mg/mL), One-Vial Formulation, Rx only, Mfd By: Dr. Reddy's Laboratories Limited, Visakhapatnam - 530 046, Andhra Pradesh, INDIA, NDC 43598-259-40. recalled?

Yes. FDA published recall D-1001-2019 on March 20, 2019. Reported hazard: Defective Container: complaint for seal and cap vial issues that could lead to a lack of sterility assurance.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DOCETAXEL.